Pfizer Successfully Launches Cejemly® (Sugemalimab Injection), an Innovative Immuno-Oncology Therapy, in China

Shanghai, February 21, 2022 /PR Newswire/ -- On February 19, 2022, Pfizer's innovative immunotherapy drug Zejia Stone^®(Common name: Sugemalimab Injection, English name: Cejemly)^®) The listing meeting was successfully held in both Shanghai and Beijing. Professor Cai-Cun Zhou, Director of the Oncology Department at Shanghai Pulmonary Hospital affiliated with Tongji University; Professor Yi-Long Wu, Honorary Director of Guangdong Provincial People's Hospital and Honorary Director of Guangdong Lung Cancer Research Institute; Professor Hui-Qiang Huang, Deputy Chief of the Internal Medicine Department at Sun Yat-sen University Cancer Center; Professor Jin Li, Director of the Oncology Department at Oriental Hospital affiliated with Tongji University; and Professor Lin Shen, Vice President of Peking University Cancer Hospital, Director of the Gastrointestinal Oncology Department, and Deputy Director of Beijing Cancer Prevention and Research Institute, were among the many renowned experts in the field of lung cancer diagnosis and treatment in China who attended the event to discuss Zejia Stone.^®Discussions and exchanges were held on topics such as the listing, new advancements in immunotherapy for non-small cell lung cancer (NSCLC), etc. Meanwhile, the conference also invited dozens of experts and scholars from other cities across China to participate online, jointly witnessing the progress of Zejia Stone.^®The Glorious Moment.

Peng Zhenke, President of Pfizer Biopharmaceuticals Group, China

Peng Zhenke, President of Pfizer Biopharmaceuticals Group, China, stated: "Pfizer always centers on patient needs and is committed to 'delivering breakthrough innovations that change patients' lives.' Pfizer actively participates in and promotes the development of lung cancer diagnosis and treatment in China, with Zejiaoshi...^®The launch of Pfizer's product in the field of oncology treatment not only reinforces its advantage in targeted precision therapy but also marks a new chapter in immuno-oncology treatment, providing Chinese cancer patients with more clinical options and accessibility. Zhejie Stone^®"The accelerated approval in China has made us feel the 'China speed.' Matching the 'China speed,' in the future, Pfizer will continue to be guided by the concept of 'Science for Victory, Together Against Cancer,' leverage its strong commercialization capabilities, and collaborate with all sectors of the industry and society to jointly promote the rapid development of targeted and immune treatments in the field of lung cancer diagnosis and treatment."

The members of the presidium jointly performed the lighting ceremony, announcing the official launch of Zhejie Stone (from left to right: Ms. Wang Yiqin, General Manager of Pfizer Biopharmaceuticals Group's Oncology Division in China; Professor Fu Xiaolong, Director of the Radiation Oncology Department at Shanghai Chest Hospital affiliated with Shanghai Jiaotong University; Professor Zhou Caicun, Director of the Oncology Department at Shanghai Pulmonary Hospital affiliated with Tongji University; and Ms. Li Xueqin, Head of the Lung Cancer Treatment Field at Pfizer Biopharmaceuticals Group's Oncology Division in China).

Selecting the Best, China Data Empowers Zhejie Stone^®Shining on the Global Innovative Drug Stage

Lung cancer is the most common type of tumor in China, and its incidence characteristics are also very different from those in European and American countries. Data from GLOBOCAN 2020 shows that the number of new cases and deaths from lung cancer in China account for 37.0% and 39.8% of the global total, respectively, making the prevention and treatment of lung cancer a significant challenge in the control of malignant tumors in China.^[1]In recent years, Chinese medical professionals and medical scientists have driven significant advancements in lung cancer diagnosis and treatment in China by addressing the real needs of Chinese patients. Particularly in the field of immunotherapy, they have effectively tackled the key challenges faced by Chinese lung cancer patients during clinical treatment. These efforts have not only transformed the overall treatment landscape for NSCLC (non-small cell lung cancer) but also greatly improved patients' long-term survival rates.

Pfizer upholds an open attitude, actively promoting and practicing the "dual-engine" strategy of "bringing in and going out." Zejiaomei^®It is the first product introduced under this strategy through active cooperation between Pfizer and innovative pharmaceutical companies in China. Thanks to the implementation of China's government innovation policies and the expedited drug review and approval process, Zejie Stone...^®On December 20, 2021, it received rapid approval from the National Medical Products Administration. This innovative immuno-oncology drug has a unique dual mechanism of action, activating dual immune pathways, and is used in combination with chemotherapy for first-line treatment of squamous and non-squamous NSCLC. To meet the needs of more patients with advanced lung cancer, Pfizer, in collaboration with all parties in the industry, mobilizes all available resources to accelerate production, logistics, distribution, and other processes for Zhejie Stone.^®Within one month of approval, it has been efficiently implemented in most provinces/autonomous regions/municipalities across China, quickly achieving commercial coverage and patient accessibility, bringing new hope to more patients in China.

Zejie Stone^®Professor Cai-Cun Zhou, Principal Investigator of the registrational Phase III clinical study GEMSTONE-302 and Director of the Oncology Department at Shanghai Pulmonary Hospital affiliated with Tongji University, shared new progress and insights on immunotherapy for lung cancer: "Zejie Stone^®With its unique dual mechanism of action, it not only activates T cells to kill tumors but also retains the antibody-dependent cell-mediated phagocytosis (ADCP) effect, activating macrophages to further attack tumors. This brings breakthrough therapeutic benefits to many lung cancer patients in China. The related clinical research results were recently published in the prestigious international journal *The Lancet Oncology*, fully demonstrating the international academic community’s recognition of the Chinese research findings. As a PD-L1 monoclonal antibody that achieves full coverage of squamous and non-squamous cancers, Zejie Stone (Zejie Stone is a placeholder for the actual product name).^®"Will enrich the existing immunotherapy options and bring more effective benefits to more patients."

Professor Cai-Cun Zhou, Director of the Oncology Department at Shanghai Pulmonary Hospital affiliated with Tongji University, shared insights on-site.

Chairman of this conference, Professor Cheng Ying, Director of Jilin Province Cancer Center; Professor Hu Yi, Head of the Oncology Professional Group at the Clinical Trial Pharmacology Base of the PLA General Hospital; Professor Wang Baocheng from the 960th Hospital of the PLA; Professor Wang Jie, Director of the Department of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences; Professor Zhou Jianying, Director of the Department of Respiratory Medicine at the First Affiliated Hospital of Zhejiang University School of Medicine; Professor Fu Xiaolong, Director of the Radiation Oncology Department at the Chest Hospital affiliated with Shanghai Jiao Tong University; Professor Song Yong, Director of the Department of Respiratory and Critical Care Medicine at Jinling Hospital affiliated with Nanjing University Medical School, and other experts stated that Zhejie Stone...^®The listing has enriched the clinical options for lung cancer immunotherapy. We look forward to Zhejie Stone.^®Bring good news to more patients.

Multidimensional Perspectives on the New Trends in Immunotherapy Development: Accelerating Clinical Benefits for More Patients

In addition to the main venue of this listing conference, Pfizer also set up two sub-venues: the "Practical Debate Session" and the "Young and Middle-aged Pioneer Dialogue Session" to discuss two major topics: common issues in clinical frontline diagnosis and treatment, and future trends in the immunotherapy era.

Each venue focuses on different topics and formats, offering a splendid array of events. The "Practical Debate" session combines theory with practice, featuring vigorous discussions on clinical cases, pooling collective wisdom to jointly explore the mechanisms and research progress of first-line resistance in driver gene-negative NSCLC, as well as new advances in immunotherapy for special patients. The "Dialogue with Young Pioneers" session gathers many young trailblazers in the field of oncology, strengthening academic foundations and sharing research outcomes from various perspectives, injecting fresh vitality into the subject of immunotherapy in the era of immuno-oncology.

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71(3):209-249.